钱多多股票论坛

trader1688.com
 FAQ FAQ RSS

支持168: Amazon Ebay Amazon(Canada)
Half


Post new topic Reply to topic  [ 544 Posts ]  Go to page 1, 2, 3, 4, 5 ... 37  Next
Author Message
 Post subject: 盘前个股动态2016
PostPosted: 1/4/16 10:09 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

for the moves in previous years, please click the following:

盘前盘后个股动态 2014-2015



 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/4/16 10:11 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

Monday 01/04/2015

8:34 am Gapping down (SCANX) : Gapping down

In reaction to disappointing earnings/guidance
: NYMX -0.9%, (filed Q3 and restated Q2 financial statements; restatement resulted in material net reduction in loss)

Select China related names showing weakness after Shanghai closed down ~7% overnight: KNDI -11.6%, JKS -10%, JMEI -9.5%, VIPS -6.5%, WBAI -5.6%, JD -5.2%, RENN -4.6%, BABA -4.5%, BIDU -4.4%, CMCM -4.2%, CTRP -3.4%, YNDX -2.5%, CMRX -1.5%

Select metal producers trading lower: BBL -4.1%, FCX -4%, MT -3.8%, VALE -3.6%, X -3.5%, RIO -2.9%, BHP -2.8%

Other news: QTWW -11% (receives non-compliance from Nasdaq relating to the minimum bid price requirement, has until June 27 to regain compliance), PLUG -7.1% (cont volatility), WTW -6.9% (pulling back following recent strength last week), QUNR -6.4% (appoints Zhenyu Chen as CEO; announces additional mgmt changes), CSIQ -5.9% (files mixed securities shelf offering), SHAK -5.3% (still checking), TTM -5% (reports Dec sales), P -4.2% (Barron's profiles cautious view), FIT -4.2% (still checking), TSLA -4% (reports Q4 deliveries at lower end of guidance), WYNN -3.9% (Macau Gaming Inspection and Coordination Bureau reported December gross gaming rev -21.2% YoY), VRX -3.8% (Pershing Square in amended 13D filing discloses it cuts stake in VRX to 8.5% from 9.9% prior), DB -3.5% (still checking), SUNE -3.5% (still checking), TWTR -3.2% (still checking), LVS -2.8% (Macau Gaming Inspection and Coordination Bureau reported December gross gaming rev -21.2% YoY), MU -2.8% (President Mark Adams will resign for personal health reasons on February 1)

Analyst comments: LEI -13% (downgraded to Sell at Euro Pacific Capital; $1 tgt), JOY -4.8% (downgraded to Sell from Neutral at UBS), NFLX -4.3% (downgraded to Neutral from Outperform at Robert W. Baird), IRBT -4% (downgraded to Neutral from Overweight at Piper Jaffray), CMG -3.1% (downgraded to Perform at Oppenheimer), PYPL -3% (downgraded to Sell at Monness Crespi & Hardt), MDRX -2.8% (downgraded to Mkt Perform from Outperform at Raymond James), AMZN -2.3% (downgraded to Neutral from Buy at Monness Crespi & Hardt), ABT -2.2% (downgraded to Equal-Weight from Overweight at Morgan Stanley), CHK -1.8% (downgraded to Underperform at Raymond James), CL -1.7% (downgraded to Sector Perform at RBC Capital Mkts), LMT -1.4% (removed from Conviction Buy List at Goldman)

8:29 am Gapping up (SCANX) : Gapping up

In reaction to strong earnings/guidance: N/A.

M&A news: ANAD +3.5% (announces that a competing bidder has made a further amended offer to acquire the co at $0.68/share, previous offer was $0.58/share)ALU +3.1% (Nokia (NOK) gains 80% control of Alcatel-Lucent (ALU) through exchange offer),NOK +2.3%,ACHC +0.9% (to acquire Priory Group for $1.89 bln in cash plus 5.363 mln shares, or ~$2.2 bln)

Select metals/mining stocks trading higher: HMY +10.9%,AUY +3.2%,AG +3.1%,AU +2.4%,AEM +2.2%,ABX +2%,GG +2%,NEM +1.6%,GDX +1.5%,GLD +1.2%,GOLD +1%,SLV +1%

Other news: UNIS +97.9% (enters into an exclusivity agreement with Amgen (AMGN)),BXLT +4.5% (Baxalta and Symphogen establish strategic collaboration to accelerate immuno-oncology),BSI +3.7% (to postpone upcoming payment of principal and interest on the Series C Debentures from January 15, 2016 until February 29, 2016)

Analyst comments: N/A

 

01/05/2015 Tuesday

 


8:32 am Gapping down (SCANX) : Gapping down
In reaction to disappointing earnings/guidance
: CMC -0.7%, LLY -0.3%

Select EU bellwhethers showing weakness: ABB -2.2%, ERIC -2.2%, SYT -2%, PHG -1.6%, ASML -1.4%, UN -1.2%, SAP -1.2%

Select oil/gas related names showing early weakness: STO -1.9%, TOT -1.8%, RIG -1.8%, SDRL -1.7%, BP -0.9%, RDS.A -0.8%

Other news: ADMS -4.7% (to offer 2.5 mln shares of its common stock in an underwritten public offering), AKBA -4.5% (announces proposed $75 mln public offering of common stock), XLRN -2.3% (filed $300 mln common stock offering; announced proposed $150 mln offering of common stock), BCS -1.1% (may be in symp with peers ING and SAN dg's today)

Analyst comments: SAN -2.1% (downgraded to Sector Perform at RBC Capital Mkts), VRSN -2.1% (downgraded to Sell from Neutral at Citigroup ), SPWR -1.6% (downgraded to Neutral from Buy at Goldman), RCL -1.3% (downgraded to Equal-Weight from Overweight at Morgan Stanley), APA -1.2% (downgraded to Underperform from Neutral at BofA/Merrill), DD -1.1% (downgraded to Neutral from Buy at Citigroup), ING -0.9% (downgraded to Sector Perform at RBC Capital Mkts), CSC -0.8% (downgraded to Equal Weight from Overweight at Barclays), JNPR -0.6% (downgraded to Mkt Perform from Outperform at Bernstein), DIS -0.5% (downgraded to Neutral from Outperform at Macquarie).

8:28 am Gapping up (SCANX) : Gapping up
In reaction to strong earnings/guidance
: SWHC +7%, MZOR +4.6%, (Q4 guidance)

M&A news: BIN +4% (confirms it has commenced review of strategic alternatives),FCS +3.8% (determines revised unsolicited proposal from China Resources and Hua Capital of $21.70/share in cash would reasonably be expected to result in a 'Superior Proposal')

Select metals/mining stocks trading higher: HMY +5.7%, MT +2.7%, AG +2.3%, FCX +1.8%, GG +1.5%, VALE +1.3%, SLV +1.2%, RIO +1.1%, NEM +1.1%, GDX +0.9%, ABX +0.9%

Other news: UNIS +28.5% (cont strength),GBSN +11.7% (announces updates to the 2016 product roadmap and status for previously announced products and FDA submissions),IMMU +7.8% (issued new patent for additional claims under the patent family 'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'),EXEL +6.6% (announced 'positive' results from subgroup analyses of the meteor Phase 3 pivotal trial)CTIC +4.1% (CTI BioPharma and Baxalta submit NDA for Pacritinib),RPRX +3.8% (expects to meet with FDA to discuss 'Complete Response Letter' for enclomiphene NDA during)February 2016GPRO +3.8% (presenting at Citi conf today),HIW +3.4% (has agreed to sell Country Club Plaza portfolio in Kansas City for $660 mln to a Taubman Centers (TCO) and The Macerich Company (MAC) joint venture),VCEL +2.8% (submits Biologics License Application to the FDA for MACI for the treatment of cartilage defects in the knee),MBLY +2.7% (GM exploring Mobileye advanced mapping with OnStar data)

Analyst comments: FSLR +4.3% (upgraded to Buy from Neutral at Goldman),JCP +1.9% (upgraded to Neutral from Sell at Citigroup),CLR +1.5% (upgraded to Buy from Neutral at BofA/Merrill),CLNE +1.4% (upgraded to Mkt Perform from Underperform at Raymond James),FMS +1.3% (upgraded to Buy from Neutral at UBS),RLYP +0.7% (initiated with a Buy at BTIG Research)

8:43 am Filings, Offerings and Pricings (:PRICE) :

Filings:

  • Acceleron Pharma (XLRN) files $300 mln common stock offering

Offerings:

  • Akebia Therapeutics (AKBA) announces proposed $75 mln public offering as part of previously disclosed shelf offering
  • Acceleron Pharma (XLRN) announces proposed $150 mln offering of common stock
  • Adamas Pharmaceuticals (ADMS) to offer 2.5 mln shares of its common stock in an underwritten public offering
  • TGTX probably soon

4:09 pm SAGE Therapeutics commences an underwritten public offering of $150 mln of its common stock (SAGE) :

 

 

http://www.streetinsider.com/Special+Reports

 

6:12 PM


Conatus Pharmaceuticals (NASDAQ: CNAT) 15% HIGHER; three-month, double-blind, placebo-controlled stage of the company’s multicenter Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 (cCK18) vs. placebo (p=0.04) in the overall patient population when adjusted for differences between treatment and placebo groups in baseline Model for End-stage Liver Disease (MELD)1 score and disease etiology as specified in the trial statistical analysis plan.


Epizyme, Inc. (NASDAQ: EPZM) 10% LOWER; announced that it intends to offer and sell up to $120,000,000 of shares of its common stock in an underwritten public offering. Epizyme intends to grant the underwriters a 30-day option to purchase up to an additional $18,000,000 of shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by Epizyme. Also, updates on Tazemetostat Phase 2; Plans Trial.


Cempra, Inc. (Nasdaq: CEMP) 7% LOWER; announced its intention to offer and sell shares of its common stock with an aggregate public offering price of approximately $175 million in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering with an aggregate public offering price of $26.25 million


Iconix Brand (NASDAQ: ICON) 5.6% HIGHER; Sports Direct International disclosed a new 9%, or 4,339,933 share, stake in the company.


Otonomy, Inc. (NASDAQ: OTIC) 5.5% LOWER; commenced an underwritten public offering of approximately $100 million of its common stock. All shares of common stock to be sold in the offering will be offered by Otonomy. In addition, Otonomy expects to grant the underwriters a 30-day option to purchase up to an additional approximately $15 million of its common stock. The number of shares to be offered and the price for the proposed offering have not yet been determined.


ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) 4.4% LOWER; intends to offer and sell, subject to market and other conditions, $300,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.


TherapeuticsMD, Inc. (NYSE: TXMD) 4.2% LOWER; announced the launch of an underwritten public offering of $125 million of shares of its common stock. TherapeuticsMD also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.


Prothena Corporation plc (NASDAQ: PRTA) 3.4% LOWER; commenced an underwritten public offering of 2,250,000 of its ordinary shares. All of the ordinary shares in the offering will be sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 337,500 of its ordinary shares.


Sonic Corp (NASDAQ: SONC) 3% LOWER; reported Q1 EPS of $0.24, $0.01 better than the analyst estimate of $0.23. Revenue for the quarter came in at $145.8 million versus the consensus estimate of $144.28 million.


bluebird bio (NASDAQ: BLUE) 1.6% HIGHER; Janney Capital initiated coverage with a Buy rating and a price target of $91.00.


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) 1% LOWER; announced a proposed underwritten public offering of 10,000,000 shares of its common stock.

 



 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/6/16 10:15 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

8:50 am Gapping down (SCANX) : Gapping down

In reaction to disappointing earnings/guidance
: SONC -4.9%, AN -4.8%, CNX -3.9%, CMG -2.9%, MSM -2.8%, MON -1.3%

Select metals stocks trading lower: BBL -7.4%, MT -7.3%, BHP -6.8%, RIO -6.6%, VALE -5.4%, FCX -4.2%, X -4%, AA -3%

Select oil/gas related names showing early weakness: LEI -5.8%, SDRL -5.8%, STO -3.9%, PBR -3.8%, RDS.A -3.6%, RIG -3.3%

Other news: EPZM -10.4% (proposed public offering of $120 mln in stock), CEMP -9.5% (to offer and sell shares of its common stock with a price of ~$175 mln in an offering), PXD -8.3% (upsizes and prices 12 mln shares of common stock at $117.00 per share), TXMD -7.6% (launched $125 mln offering of common stock), SAGE -7.5% (filed mixed securities shelf offering for an undisclosed amount,  commenced an offering of $150 mln of its common stock), OTIC -5.7% (announced $100 mln stock offering), ACAD -5.1% (proposed public offering of $300 mln in shares of common stock), ESV -3.3% (receives notice from Petrobras (PBR) asserting that Petrobras believes the DS-5 drilling services contract is void effective January 4), VRX -3.2% (looking to appoint a new CEO as Michael Pearson remains hospitalized, according to the WSJ), PRTA -3% (commenced an underwritten public offering of 2.25 mln of ordinary shares), SWHC -2.9% (modest pull back following yday's strength), ASML -2.9% (in symp with AAPL), XLRN -2.7% (prices offering of 3,750,000 shares of common stock at $40.00 per share), UN -2.4% (still checking), NXPI -2.2% (in symp with AAPL), AAPL -2.2% (cont weakness following yday's nikkei story)

Analyst comments: QLIK -4.3% (downgraded to Sector Weight from Overweight at Pacific Crest), HSBC -4.1% (downgraded to Underweight at JP Morgan), WDAY -2.9% (downgraded to Equal Weight from Overweight at Barclays), MASI -2.9% (downgraded to Outperform from Strong Buy at Raymond James), CHKP -2.6% (downgraded to Underweight from Equal Weight at Barclays), HCP -2.6% (downgraded to Underweight from Equal Weight at Barclays), H -2.5% (downgraded to Neutral from Overweight at JP Morgan)

8:45 am Gapping up (SCANX) : Gapping up

In reaction to strong earnings/guidance
: N/A.

M&A news: AMIC +20.8% (Co and Independence Holding (IHC) announced sale of stop loss business to Swiss Re Corporate Solutions for $152.5 mln in cash)

Select metals/mining stocks trading higher: HMY +7%, AEM +2.3%, AUY +2.1%, AU +1.9%, GFI +1.4%, NEM +1%, GG +0.9%, ABX +0.9%, SLW +0.8%

Other news: CNAT +23.7% (achieved positive results with Emricasan in initial stage of Phase 2 liver cirrhosis clinical trial),OXGN +7.1% (confirms the FDA granted orphan drug designation to CA4P for the treatment of neuroendocrine tumors),MBLY +6.3% (signs Memorandum of Understanding with Volkswagen (VLKAY) and announces a strategic partnership to explore and integrate REM into Volkswagen's fleet),VICL +5.2% ( confirms the FDA granted Orphan Drug Designation for VL-2397 for the treatment of invasive aspergillosis),KANG +4.5% (cont strength),HLTH +2.5% (intended to restate consolidated financial statements for FY14 and for 2015 interim periods),WATT +1.4% (introduced the first miniature WattUp transmitter design that is both small and cost effective enough to ship in-box with small wearable and IoT devices.)

Analyst comments: TASR +3.2% (upgraded to Overweight from Neutral at JP Morgan)

Filings:

  • SAGE Therapeutics (SAGE) files mixed securities shelf offering for an undisclosed amount and commences an underwritten public offering of $150 mln of its common stock

Offerings:

  • Acadia Healthcare (ACHC) proposes 10 mln share common stock offering
  • ACADIA Pharmaceuticals (ACAD) announces proposed public offering of $300 mln in shares of common stock
  • Cempra (CEMP) to offer and sell shares of its common stock with a price of ~$175 mln in an offering
  • Prothena (PRTA) commences an underwritten public offering of 2.25 mln of ordinary shares
  • TherapeuticsMD (TXMD) launches $125 mln offering of common stock
  • Epizyme (EPZM) announces proposed public offering of $120 mln in stock
  • Otonomy (OTIC) announces $100 mln stock offering
  • TGTX probably soon

Pricings:

  • Pioneer Natural Resources (PXD 125.17) upsizes and prices 12 mln shares (Originally planned to offer 10.5 mln) of common stock at $117.00 per share. 
  • Acceleron Pharma (XLRN 40.22) prices offering of 3.75 mln shares of common stock at $40.0/share
  • ESSA Pharma (EPIX 4.65) announces 4.54 mln share private placement at $3.30/share


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/7/16 11:10 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

Gapping down
In reaction to disappointing earnings/guidance
: CLBS -32.1%, (provides 2015 and 2016 revenue guidance; announces an increased focus of its strategic priorities ), FINL -16.2%, RECN -6%, COST -2.5%, WBA -2%, KBH -1.6%, SIG -1.4%,

M&A news: ATML -8.3% (Bloomberg reporting that Microchip (MCHP) is reconsidering its interest in Atmel amid their continued business struggles), .

Select China related names showing weakness: JKS -6.7%, BABA -5%, CSIQ -4.7%, SOHU -4.7%, JD -4.6%, BITA -4.6%, BIDU -4.6%, CMCM -4.6%, WBAI -4.4%, SFUN -4.3%, JMEI -4.2%, YY -3.9%

Select metals stocks trading lower: VALE -6.5%, BBL -6.3%, RIO -5.1%, MT -4.9%, FCX -4.4%, X -3.5%, AA -3.4%

Select oil/gas related names showing early weakness: WLL -9%, SSL -7.5%, BHP -6.3%, SDRL -6%, BP -5.2%, RDS.A -5.2%, PBR -4.8%, RIG -4.3%, KMI -3.9%, STO -3.5%, SLB -2.7%

Other news: TLOG -67.6% (announces that its Phase 2 study of birinapant co-administered with azacitidine in first line higher risk patients suffering from myelodysplastic syndromes did not demonstrate any clinical benefit over placebo), EPZM -23.3% (prices offering of 13,333,334 shares of its common stock at $9.00 per share), ARDX -15.1% (commences an underwritten public offering of up to $75 mln of shares of its common stock, updates guidance on the projected timing of its clinical trials for its lead product candidate, tenapanor ), GALE -13.2% (to offer shares of its common stock and warrants to purchase its common stock in an underwritten public offering), AKBA -11.5% (prices 7,250,000 shares of common stock at $9.00 per share), SAGE -6.8% (prices 3,157,894 shares of its common stock at $47.50 per share), ADMS -6.4% (prices offering 2,500,000 shares of its common stock at $23.00 per share), CEMP -6.2% (prices its downsized underwritten public offering of ~4.17 mln shares of its common stock at $24.00/share), PSDV -5.3% (proposed a common stock offering for an undisclosed amount), ACAD -4.6% (prices offering of 10,344,827 shares of its common stock at $29.00 per share), PRTA -2.9% (prices underwritten public offering of 2.25 mln of its ordinary shares at $53.00/share), ERI -2.3% (announced the departure of its COO and CFO)

Analyst comments: EXPD -7.8% (downgraded to Sell at UBS), EVDY -4.9% (downgraded to Hold from Buy at Stifel), ILMN -3.9% (downgraded to Market Perform from Outperform at Wells Fargo), PAYX -3.8% (downgraded to Underperform from Neutral at BofA/Merrill), APC -3.7% (downgraded to Hold from Buy at Deutsche Bank), CMG -3.2% (target lowered to $450 from $500 at Wedbush), HPQ -3% (downgraded to Market Perform from Outperform at Wells Fargo), AAPL -2.5% (target lowered to $130 at RBC Capital Mkts), BRCM -1.5% (downgraded to Mkt Perform from Outperform at Bernstein)

8:42 am Gapping up (SCANX) : Gapping up
In reaction to strong earnings/guidance/SSS
: NSPH +37.9%, MGCD +13.3%, (also reports unresolved manufacturer issue), ZUMZ +11.1%, (Zumiez reports December comparable sales -8.9% vs -13.8% Retail Metrics consensus; raises Q4 outlook based primarily on better than expected sales), MG +7.2%, FRAN +2.8%, GBX +1.9%, PLCE +1.3%, M +1.1%, (Macy's reports November and December comp store sales declined 4.7% y/y; Lowers 2015 EPS guidance), QUAD +0.8%

M&A news: EZCH +2.8% (Raging Capital supports transaction with Mellanox (MLNX))

Select gold/silver stocks trading higher: HMY +9.8%, GFI +3.3%, ABX +2.3%, NEM +2.2%, AEM +2.1%, GOLD +2%, GDX +1.5%, PAAS +1.3%, .

Other news: CRDC +42.9% (amended license agreement with Intuitive Surgical (ISRG)),DVAX +29.8% (reports top line results of Phase 3 HEPLISAV-B study; Both co-primary endpoints were met),BIND +14.7% (Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer),QURE +12% (announced it will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial tomorrow morning),MSTX +7% (provides business update, Enrollment in largest-ever interventional Phase 3 trial in sickle cell disease has surpassed 90%),ZIXI +2.7% (approves $15 mln share repurchase program),DNN +2.7% (announced that preparations for its 2016 uranium exploration programs in the Athabasca Basin have commenced and that exploration drilling is scheduled to begin on January 12),CCO +2.5% (following late move higher on LAMR asset interest)

Analyst comments: N/A


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/8/16 10:07 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

8:40 am Gapping down (SCANX) : Gapping down
In reaction to disappointing earnings/guidance
: TCS -27.6%, CUDA -26.4%, AEO -11.1%, GHDX -8.9%, QDEL -8.1%, GPS -7.4%, QRVO -5.2%


Select metals/mining stocks trading lower: HMY -8.3%, KGC -5%, AUY -4.3%, ABX -3.3%, SAND -3.3%, GG -2.5%, GDX -2.4%, GFI -2.2%, NEM -1.9%, SLV -1.5%, GOLD -0.8%

Other news: SFXE -32% (disclosed it retained financial advisory firm FTI Consulting to serve as its Chief Restructuring Officer, cautioned it may consider utilizing the available protections under the federal bankruptcy laws), SORL -8.7% (announces that the consortium has withdrawn its previously submitted non-binding 'going-private' offer due to market conditions), COLL -2.7% (prices a 2.75 mln share public offering of common stock at $20.00/share), NVCR -1.3% (submitted a premarket approval partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency for the use of Optune in patients with newly diagnosed glioblastoma), SWKS -0.9% (following CRUS guidance), AVGO -0.5% (following CRUS guidance).

Analyst comments: N/A

8:36 am Gapping up (SCANX) : Gapping up
In reaction to strong earnings/guidance
: RT +4.6%, RTIX +2.8%, TSM +2.4%, CRUS +2.1%, FIVE +1.2%, (Five Below raises Q4 rev guidance and narrows Q4 EPS guidance; holiday comps +4.1%), BBBY +1.1%, URBN +0.6%, (Urban Outfitters reports Nov/Dec total company net sales were flat y/y, comparable retail segment (including direct- to-consumer channel) net sales -2%), .

M&A news: SHPG +2.6% (Potential Shire (SHPG) acquisition of BXLT at $48/share),BXLT +1.8% (Potential Shire (SHPG) acquisition of BXLT at $48/share)

Select China related names showing strength: YNDX +3.9%, WBAI +3.4%, CHU +2.8%, CHL +2.6%, HSBC +1.9%.

Select alt energy stocks trading higher: FCEL +12.8%, JKS +8.9%, CPST +7.1%, CSIQ +5.7%

Select oil/gas related names showing strength: CHK +3.6%, PBR +3.1%, SDRL +2.1%, DVN +1.6%, KMI +1.4%, COP +0.8%

Other news: SIEN +40.8% (Sientra sends letter to surgeons regarding the independent third-party testing of Sientra's products, the submission of such test results to the FDA and other business updates),XBIT +18.1% (completes data analysis for its Phase III European study),ATHX +14.6% (Athersys and Healios form alliance focusing on development and commercialization of regenerative medicine products for stroke in Japan),BCLI +10% (still checking),NGL +7.7% (announced that it has entered into an agreement with an affiliate of ArcLight Capital Partners to sell TransMontaigne GP LLC for $350 mln in cash),WTW +4.6% (cont volatility),DDD +4.2% (likely due to CES presentation),MNTA +4.1% (enters into an exclusive global collaboration agreement with Mylan (MYL)),ARDX +4% (prices 7.5 mln shares of its common stock at $10.00 per share),ARIA +3.8% (Ariad Pharm and its partner Otsuka Pharma submit NDA to the Japanese Pharmaceuticals and Medical Devices Agency seeking approval for Iclusig),FOMX +3.2% (announces positive results from a Phase 1 maximum use pharmacokinetics study of FMX-101, top line results indicate that the relative bioavailability of FMX-101 was more than 100x lower than that for Solodyn),GPRO +2.6% (cont vol pre-mkt),TWX +2.6% (could be forced to pursue a sale, or spin-off its HBO unit by activist shareholders, according to the NYPost),VRX +2.2% (cont vol pre-mkt),F +2.1% (reports Ford China sold a record 1.1 mln vehicles in 2015; December sales set a record, up 27%),CRH +1.4% (provides strategy update; confirms total disposal proceeds of EUR1 bln for 2015),NXPI +1.3% (following CRUS guidance)

Analyst comments: SGNL +17.6% (initiated with a Buy at Rodman & Renshaw; tgt $4 on favorable MyPRS view),SUNE +12.6% (upgraded to Hold from Sell at Axiom Capital),ARC +2.3% (initiated with a Buy at B. Riley & Co),PHM +1.7% (upgraded to Outperform from Mkt Perform at Raymond James),AA +1.7% (upgraded to Outperform from Neutral at Macquarie),FL +1.5% (upgraded to Buy from Neutral at BofA/Merrill),MSFT +1.1% (initiated with an Outperform at BMO Capital)



 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/11/16 10:23 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

Monday 1/11/2016

8:22 am Gapping down (SCANX) : Gapping down
In reaction to disappointing earnings/guidance
: QGEN -11.8%, VRTX -4.6%, GCO -4%, EXAS -3%


Select China related names showing weakness with the Shanghai down over 5% last night: JD -2.2%, JMEI -1.7%, JKS -1.5%, CSIQ -0.9%, VIPS -0.9%, SFUN -0.9%, YY -0.7%, CTRP -0.6%

Other news: ACI -64% (files Chapter 11 bankruptcy, agrees on terms of debt restructure deal with Senior lenders), ASTI -12.9% (files 48 mln share common stock offering by a selling stockholder), NURO -5.6% (files ~16.505 mln share common stock offering issuable upon conversion of outstanding shares of Series C Preferred Stock & upon exercise of certain outstanding warrants by selling securityholders), BCLI -2.9% (enters into collaborative agreement with Hadassah Medical Center in Jerusalem), CYTK -1.9% (presents analyses demonstrating predictive value of slow vital capacity for clinical outcomes in ALS)

Analyst comments: UA -4.3% (downgraded to Underweight from Equal-Weight at Morgan Stanley), VFC -2.3% (downgraded to Underweight from Equal-Weight at Morgan Stanley), MJN -1.8% (downgraded to Neutral from Overweight at JP Morgan), WETF -1.4% (downgraded to Sell from Neutral at Goldman), JPM -0.5% (downgraded to Neutral from Buy at Goldman)

8:16 am Gapping up (SCANX) : Gapping up
In reaction to strong earnings/guidance/SSS
: SQNM +6%, IRMD +5.8%, HCA +5.2%, KONA +4.9%, (prelim Q4 restaurant sales above consensus) ACOR +4.6%, (reports prelim Q4/2015 AMPYRA sales and 2016 guidance), SCVL +4.5%, EBS +3.3%, NVRO +3.1%, FOLD +2.5%, (Provides Full-Year 2016 Strategic Outlook and Financial Guidance) EVHC +0.8%, ARAY +0.7%

M&A news: AFFX +48.6% (to be acquired by Thermo Fisher (TMO) for $14.00/share in cash; expected to be immediately accretive to TMO's adjusted EPS),APOL +8.2% (exploring strategic alternatives; also released earnings),BXLT +6% (to be acquired by Shire (SHPG) for ~$45.57/share),JUNO +4.6% (acquires AbVitro for ~$78 mln),EBS +3.3% (receives IRS ruling for the planned spin-off of its biosciences business), SHPG +2.9% (to acquire BXLT for 45.57 per share),M +1.6% (Starboard sends letter to the Board encouraging them to pursue more real estate deals, according to the WSJ)

Select metals/mining stocks trading higher: MT +8.4%, HMY +6.2%, GFI +3.9%, KGC +3.7%, AU +2.4%, RIO +1.7%, VALE +1.5%, GOLD +1%

Other news: ATV +36.4% (announces share repurchase program of $2 mln),SCON +35.2% (reported its Conductus wire achieved a significant milestone for use in High Field Magnet applications),AVXL +21.1% (announces positive dose-response data for ANAVEX 2-73 in Alzheimer's disease patients),THLD +13.9% (Threshold Pharma and Merck KGaA (MKGAY) agree upon terms for the licensing back of all rights to evofosfamide to Threshold),SGYP +12.3% (announces positive phase 1b data with its second uroguanylin analog),VPCO +11.6% (withdrew previously announced offer to issue common stock and warrants in exchange for outstanding Units sold in the July 2015 offering),MNKD +6.1% (confirms Sanofi's (SNY) termination of the License and Collaboration Agreement),OCUL +5.6% (appoints Jonathan H. Talamo, M.D., as Chief Medical Officer),ZGNX +5.6% (Initiation of Phase 3 Program for ZX008 in Dravet Syndrome),ACRX +5.5% (provides anticipated 2016 milestones; reports initiation and completion of final Phase 3 trial in the U.S. for Zalviso, NDA Resubmission),ONTY +5.5% (announces the retirement of President and CEO Robert L. Kirkman, M.D. effective January 11),SGMO +4.6% (details its milestones and objectives for 2016),WLH +4.2% (commences $50 mln of 7.00% Senior Notes due 2022),RXDX +3.8% (details its strategic priorities for 2016),ILMN +3.5% (forms new company GRAIL for early detection blood-based screening; considered significant development in the war on cancer),SCMP +3.2% (granted a sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America from Cancer Prevention Pharma),IMGN +2.8% (provides anticipated milestones for 2016),CTIC +2.5% (reports positive progress of lead clinical programs; provides outlook for 2016),ARIA +2.4% (elects Alex Denner as Chairman),AA +2% (announces $1.5 bln long-term contract with GE Aviation (GE) for jet engine components; note AA reports earnings tonight),HMSY +1.4% (discloses it & the New York State Office of the Medicaid Inspector General entered into an amendment extending the term of existing third party liability contract),XONE +1.4% (enters into an At Market Issuance Sales Agreement with FBR and MLV & Co. to sell up to $50 mln in shares of its common stock),GPRO +1.4% (slight strength following Friday's weakness),NVS +1.3% (signs licensing agreement with Surface Oncology),MEG +1.3% (Nexstar Broadcasting (NXST) reiterates its commitment to acquire Media General, and to take all necessary actions to consummate a transaction)

Analyst comments: GM +1.9% (upgraded to Outperform from Neutral at Credit Suisse),AAPL +1.4% (upgraded to Buy from Neutral at Mizuho),WFC +1.1% (upgraded to Buy from Neutral at Goldman)

Tuesday 1/12/2016

8:44 am Gapping down (SCANX) : Gapping down
In reaction to disappointing earnings/guidance
: SKUL -22.9%, SHOO -1.4%, HTWR -1.4%, IONS -1.4%, RCI -1.2%, NVDQ -0.8%, TISI -0.5%


Select metals/mining stocks trading lower: GFI -1.9%, NEM -1.5%, GG -1.5%, KGC -1.2%, BHP -1.2%, ABX -1.2%, SLW -0.8%, RIO -0.7%, GLD -0.6%, BBL -0.5%, SLV -0.5%

Other news: EGO -8.5% (amended investment plans in Greece), PBR -2.7% (confirms adjustments to the 2015-2019 Business and Management Plan; reduced CapEx by $32 bln), EDR -2.6% (prices offering of 5.5 mln common stock at $35.50 per share), LYG -1.5% (still checking), GOOD -1.3% (filed $500 mln mixed securities shelf offering)

Analyst comments: NGL -2% (downgraded to Hold from Buy at Stifel)

8:40 am Gapping up (SCANX) : Gapping up
In reaction to strong earnings/guidance
: BURL +12.3%, ELOS +9.7%, HZNP +8.8%, LULU +8.7%, UCTT +5%, ACLS +4.2%, TACO +3.7%, SAP +3%, ABMD +2.5%, EXPR +2.5%, BIG +2.4%, CAH +1.7%, CTSH +1.6%, ASNA +0.7%, CRAY +0.6%, XENT +0.4%

M&A news: APOL +19.7% (following report that Apollo Global Management (APO) nearing deal to buy Apollo Education),PHG +2.8% (Sky News report of potential Melrose bid for lighting unit),SNN +1.8% (announces the acquisition of BST-CarGel)

Select EU related names showing strength: LUX +4.1%, NVO +2.6%, ABB +2%, UN +1.8%, SNY +1.5%, ASML +1.3%, STM +1.1%

Other news: SNOW +28.2% (announces modified 'Dutch auction' self-tender offer to purchase up to $50 mln of common stock with cash),BIOC +19.7% (entered into an agreement with Blue Cross Blue Shield of Illinois allowing its members access to Biocept's menu for liquid biopsy testing),BLRX +17.5% (announces collaboration with Merck (MRK) on Phase 2 study investigating BioLineRx's BL-8040 in combination with KEYTRUDA),BCLI +15.1% (Jama Neurology releases Promising Data from ALS Clinical Trial),PSTI +9.5% (receives FDA approval to begin PLX-R18 clinical trial),CLLS +8% (announced the publication of a study describing the design and development of a new CAR architecture with an integrated switch-on system that permits control over CAR T-cell functions),XONE +8% (to raise ~$13 mln in gross proceeds in a registered direct offering of common shares from its Chairman and CEO),AVP +6.1% (modest rebound following last week's decline),TEDU +3.8% (Strategic Partnership with Alibaba Cloud Computing Co),SUNE +3.3% (modest rebound following last week's decline),BAS +2.8% (reports December op data; expect Q4 revenues to be at the higher end of the range that previously announced),PODD +2.3% (entered into development agreement with Eli Lilly (LLY) for OmniPod delivery of U200 concentrated insulin),TSLA +2% (trading higher with the mkt),SBUX +1.6% (on-track w/ 2K stores in China),JBLU +1.3% (in symp with AAL),NFLX +1% (trading higher with the mkt),AAL +1% (reports Dec traffic)

Analyst comments: SHPG +5.5% (upgraded to Outperform from Neutral at Credit Suisse),CIEN +3.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley),AAPL +1.8% (upgraded to Buy from Neutral at BofA/Merrill),INTC +1.7% (upgraded to Buy at Mizuho),KO +1.6% (upgraded to Buy from Hold at Stifel),AMZN +1.2% (target raised to $800 from $777 at Credit Suisse)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/13/16 10:19 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 51735.html

8:28 am Gapping down (SCANX) : Gapping down

In reaction to disappointing earnings/guidance
: MFLX -16.8%, F -2.8%, (Ford Motor sees record 2015 adj. pre-tax profit at the high end of guidance, with 2016 adj. profit equal to or higher; announces $0.25 special dividend), TSCO -2.7%, CSX -1.9%, FANG -1.3%, STJ -0.4%


Other news: FXCM -14.5% (FXCM reports December and Q4 metrics; Says ongoing sales process may not be completed in Q1 as previously indicated), HQCL -2.4% (sells a portfolio of three operating PV power plants in the UK for ~$90 mln plus working capital to the NextEnergy Solar Fund), EQY -1.7% (commences a public offering where it will sell ~11.3 mln shares of co common stock ), FANG -0.9% (guides Q4 2015 production and FY16 production; announces 2.25 mln common stock offering)

Analyst comments: LYG -2.7% (downgraded to Underperform at Exane BNP Paribas), AXP -1.4% (downgraded to Neutral from Buy at Goldman), CONN -1% (downgraded to Hold from Buy at Stifel)

8:26 am Gapping up (SCANX) : Gapping up

In reaction to strong earnings/guidance
: HLTH +32.1%, ARO +17.7%, (Aeropostale announces new cost reduction program; reiterates Q4 guidance for EPS of ($0.17)-(0.04) vs. ($0.12) Capital IQ Consensus Estimate), TREE +4.5%, ACST +4.5%, GM +4.4%, YUM +2.6%, ( discloses China December comps +1%), IRG +2%, (Ignite Restaurant announces Q4 prelim sales at $93.3 mln vs. $91.0 Capital IQ Consensus Est; Comparable Sales -2.9%), SYK +1.5%, PRGS +1.1%, SVU +1%, NEPT +0.8%

M&A news: CYBR +11.1% (Check Point Software (CHKP) in early-stage talks to acquire Cyber Ark, according to Haaretz),ORAN +0.9% (to acquire Airtel's subsidiaries in Burkina Faso and Sierra Leone)

Select metals/mining stocks trading higher: HMY +5.2%, X +4.9%, VALE +3.8%, RIO +3.6%, FCX +2.9%, MT +2.3%, BHP +1.8%, AA +1.5%

Select oil/gas related names showing strength: ETE +3.8%, WLL +3.5%, BP +2.1%, OAS +2%, RDS.A +0.9%, XOM +0.7%, PBR +0.6%

Other news: TTNP +33.3% (Titan Pharma and Braeburn Pharmaceuticals receive FDA recommendation for Probuphine),BIOL +10.9% (enters into a development and distribution agreement with IPG Photonics Corporation's (IPGP) medical laser division),MET +8.4% (MetLife plans to pursue the separation such as public offering, spin-off, or sale of a substantial portion of its U.S. Retail segment ),QUNR +7.5% (Ctrip.com announced it has agreed to make certain investments; investment entities will acquire a significant minority stake of Qunar Cayman Islands),ARNA +5.7% (Arena Pharm and Boehringer Ingelheim to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor),NAT +5.1% (increases quarterly dividend to $0.43/share from $0.38/share),EURN +4.5% (modestly rebounding after recent decline),FEYE +4.2% (in symp with CYBR),SALT +4% (reports Scorpio Services Holding has purchased 338,436 common shares at an average price of $4.64 per share previous announcement on Oct 1, 2015),ARTX +3.6% (announced that its Training and Simulation Division has received $7.4 mln in new awards and contract modifications),AIG +3.1% (in symp with MET),SHPG +2.1% (cont strength),DKS +1.9% (The UK's Sports Direct discloses stakes in Dick's and Iconix Brand Group (ICON)),ERII +1.7% (announces $6 mln share repurchase program)

Analyst comments: LNG +3.8% (upgraded to Buy from Neutral at Citigroup),PHM +2.2% (upgraded to Overweight from Neutral at JP Morgan),MSFT +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley),QCOM +1.5% (upgraded to Positive from Neutral at Susquehanna)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/14/16 10:23 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

8:34 am Gapping down (SCANX) : Gapping down
In reaction to disappointing earnings/guidance
: GPRO -26.4%, (lowers Q4 guidance; will cut workforce by ~7%; SVP of Entertainment resigns, takes Board seat), PSG -15.6%, BBY -8.6%, SAR -3.5%, ATML -3.1%, WTR -1.9%

Select EU related names showing weakness with the DAX -2%+ today: IHG -4.2%, DB -2.1%, CS -1.5%, RCL -1.5%, RACE -1.3%, CCL -1.3%, BCS -1%


Other news: CGG -24.8% (following yesterday's rights offering), AMBA -10% (in symp GPRO guidance), AUY -2.2% (provides preliminary 2015 operational results; also downgraded to Equal Weight from Overweight at Barclays), SBUX -0.5% (issues statement on Jarkarta attacks; reports indicate explosion occurred in one of its stores)

Analyst comments: YELP -6.5% (downgraded to Sell from Neutral at B. Riley & Co), NVDA -2.6% (downgraded to Underweight from Equal Weight at Barclays), UBNT -2% (downgraded to Mkt Perform from Outperform at Bernstein)

8:31 am Gapping up (SCANX) : Gapping up
In reaction to strong earnings/guidance
: BGFV +6.8%, INFY +5.7%, MTN +3.3%, (Season-to-date lift ticket rev +19.4%; expects to exceed EBITDA guidance ), JPM +1.8%, CLC +1.6%, WNS +1.1%, BCE +0.5%

M&A news: WBMD +7.1% (in talks with a number of potential buyers over parts or all of its business, according to the FT),FORTY +2.9% (Formula Systems and Israel Aerospace Industries acquire military unit of Ness Tech (:NSTC) for $50 mln)

Select financial related names showing strength after JPM earnings: MS +1.6%, C +0.8%, BAC +0.7%

Select metals/mining stocks trading higher: HMY +3.9%, BBL +2.4%, VALE +2.2%, BHP +1.8%, RIO +1.5%

Select oil/gas related names showing strength: EPE +5.8%, SN +3.9%, TOT +2.7%, BP +2.3%, OAS +2%, COG +1.8%, RDS.A +1.2%, CHK +1.1%

Other news: IPCI +11.8% (announces successful bioequivalence results for abuse deterrent Rexista Oxycodone XR),MNKD +5.1% (cont pre-mkt volatility),ERIC +2.4% (extends patent cross license agreement with Huawei)

Analyst comments: TRGP +5.3% (upgraded to Buy from Hold at Jefferies),CMG +1.8% (upgraded to Buy from Outperform at Credit Agricole)

8:42 am Sarepta Therapeutics pops then pulls back after FDA does not approve BioMarin's (BMRN) DMD (muscular dystrophy) drug; SRPT AdCom is next Friday (SRPT) :

  • The Advisory Committee for SRPT's DMD drug is Jan 22; PDUFA date is Feb 26.
  • BMRN: FDA has concluded that the standard of substantial evidence of effectiveness has not been met. BioMarin is reviewing the Complete Response Letter and will work with the FDA to determine the appropriate next steps regarding this application.
  • The AdCom did not go well so this news isn't a huge surprise; BMRN slightly higher after initially dropping.


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/15/16 10:24 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

Gapping down
In reaction to disappointing earnings/guidance
: INTC -5.4%, ADI -2.5%, SLP -2.2%, USB -2%, C -1.5%, WFC -1.3%, RF -1.1%, EURN -0.6%

M&A news: GE -1.4% (to divest its Appliance unit to Haier for $5.4 bln)

Select China related names showing weakness with Shanghai -3.5% overnight: CSIQ -9.7%, FCX -6.4%, JMEI -4.8%, JD -4.3%, WBAI -4%, HSBC -3.6%, BABA -3.2%, BIDU -3%

Select semi/PC related stocks trading lower following INTC earnings: STM -4.3%, SWKS -3.8%, ARMH -3.7%, ASML -3.5%, MU -3.1%

Select oil/gas related names showing early weakness: ETE -8.6%, WMB -7.9%, PBR -7.5%, RIG -6.2%, MRO -6.1%, CHK -5.7%, STO -5.4%, RDS.A -5.4%, SSL -5.2%, BP -5.2%, APC -4.3%, PTR -4.1%, BHI -4.1%, HAL -3.9%, DVN -3.7%, SLB -3.2%

Other news: SDRL -9.5% (agrees to delay delivery of 2 ultra-deepwater drillships), BHP -7.6% (to write down ~$4.9 bln on US oil and gas assets), BIOA -5.1% (commenced public offering of its common stock), AKRX -4.4% (engaged BDO USA as the co's independent registered public accounting firm; estimates of errors resulted in an overstatement to net revenue and pretax income from continuing operations of ~$35 mln), GPRO -4% (cont weakness), NFLX -3.8% (trading lower with the futures), TASR -3.7% (The U.S. patent office has confirmed the validity of Co's '292 patent on body camera auto-activiation technology; Co also files lawsuit against TASER (TASR)), ATVI -3.2% (Vivendi (VIVHY) sells remaining stake in ATVI), EPR -3% (prices offering of 2,250,000 of its common shares; terms not disclosed), FCAU -2.5% (reports Dec sales), MRK -1.6% (resolves previously disclosed securities class action lawsuit related to Vioxx for ~$680 mln), GS -1.4% (confirms settlement with RMBS working group; will reduce earnings Q4 earnings by $1.5 bln)

Analyst comments: CNHI -5.9% (initiated with a Underperform at Credit Suisse), GRMN -5.3% (downgraded to Underperform from Neutral at Credit Suisse), H -4.2% (downgraded to Sell from Neutral at Goldman), DIS -3.2% (downgraded to Underweight at Barclays)

8:21 am Gapping up (SCANX) : Gapping up
In reaction to strong earnings/guidance
: SEED +12.5%, WYNN +4.9%, SKY +2.4%, EDUC +2.2%, FAST +2%

M&A news: CDRB +16.1% (enters into a non-binding Letter of Intent to engage in a merger with Aegis Identity Software ),SYT +2.4% (Bloomberg reports that Syngenta's (SYT) Board would support a potential deal with ChemChina)

Select metals/mining stocks trading higher: HMY +9.4%, AU +4.7%, MTL +3.5%, MTL +3.5%, ABX +2.4%, GDX +2%, NEM +1.6%, GLD +1.1%

Other news: BSI +24% (receives additional offer to purchase its holdings in Blue Square Real Estate),DGLY +8.8% (The U.S. patent office has confirmed the validity of Co's '292 patent on body camera auto-activiation technology; Co also files lawsuit against TASER (TASR)),LVS +2.8% (in symp with WYNN),AE +2.1% (subsidiary acquired a 30% member interest in Ben Cap for $2.2 mln),BTG +1.4% (reported Q4 gold production +18% y/y to of 131,469 ounces and issues 2016 production outlook for gold production of 510-550K ounces),MGM +1.4% (in symp with WYNN),LEI +0.9% ( schedules conference call to discuss planned Mid-Continent acquisition and strategic objectives on January 21 at 11am ET)

Analyst comments: ESL +5.4% (upgraded to Outperform from Neutral at Credit Suisse),EA +1.2% (upgraded to Buy from Neutral at BofA/Merrill),SHPG +0.8% (upgraded to Buy from Neutral at BofA/Merrill)


9:03 am Sarepta Therapeutics now lower by 53% following the release of disappointing FDA Briefing documents (SRPT) :

  • As mentioned earlier, the FDA released Briefing documents ahead of a 1/22 advisory committee meeting.
  • The Briefing docs conclude that "the data, overall, did not provide statistical evidence to support efficacy of eteplirsen in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping."
  •  Further, the doc says that "the comparison of eteplirsen with historical controls, as proposed by the applicant in the open-label extension of Study 201 (called Study 202 by the applicant), is statistically uninterpretable, as this open-label extension did not have a prespecified statistical analysis plan, and had an inadequate control for bias."
  • Eteplirsen is SRPT's lead DMD product candidate.
  • On 1/14, competitor Biomarin Pharm (BMRN) received Complete Response Letter from the FDA regarding its NDA for Kyndrisa for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
  • SRPT is trading at $14.85 in the pre-market, -53% on the day. See 8:20 & 8:40 comments for more details.
"Although the FDA does not comment on drugs under review, it traditionally has wanted to avoid appearing to be swayed by patients or politics, which may explain what appears to be an overwhelming negative review of the data submitted by Sarepta. The documents will form the basis of a discussion next Friday, Jan. 22, where patients and the company will have a chance to respond."

The FDA Briefing Information and the Company Briefing Information posted by the FDA may be obtained by following this pathway to the FDA web site: [http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/ucm478063.htm].



 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/19/16 10:52 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

8:39 am Gapping down (SCANX) : Gapping down

In reaction to disappointing earnings/guidance: TIF -3.9%, (reports holiday comps; guidance WIT -0.5%

M&A news: SU -1.9% (Suncor Energy and Canadian Oil Sands (COSWF) amend acquisition offer), SAND -0.9% (Sandstorm Gold (SAND) has agreed to acquire 56 royalties from co for $22 mln)

Other news: EBIO -52.3% (Phase 3 data on Isunakinra which missed primary endpoint of ocular itching), EC -4.9% (Moody's downgraded Ecopetrol to Baa3-triggered by persisting stressed oil prices; placed ratings on review for further downgrade), HDP -3.2% (files $100 mln common stock offering; also raises Q4 guidance (in line with estimates)), FTK -3% (announces retention of MHA Petroleum Consultants by CnF Special Technical Committee; Announces select, preliminary Q4 results; appointment of Independent Board Committee and SEC inquiry), SYT -2% (cont pre-mkt vol surrounding M&A spec), PBR -1.5% (reports its oil and natural gas production for 2015; period average of 2.128 mln barrels per day was 4.6% higher than the previous year ), HMY -1.2% (still checking), BLCM -0.5% (files $150 mln mixed securities shelf offering)

Analyst comments: SRPT -2.7% (downgraded to Sector Perform at RBC Capital Mkt)


8:38 am Gapping up (SCANX) : Gapping up

In reaction to strong earnings/guidance: UN +4.5%, MS +3%, DAL +2.2%, BAC +2%, SN +1.1%, CMA +1.1%, UNH +0.8%, FHN +0.8%, MTB +0.5%

M&A news: BITI +80.8% to be acquired by Acorda (ACOR) for $25.60 per ADS),RSE +26% (Brookfield Asset Management (BAM) proposes to acquire Rouse for $17.00/share in cash),SUNE +5.8% (acquires 33% stake in remaining 231 megawatt portion of Dominion's (D) 567 megawatt solar portfolio for $117 mln and sells said stake to Terra Nova for same price),ERIC +4.4% (Ericsson to acquire FYI TV),SHPG +3.1% (Barron's profiles positive view on Shire (SHPG) based on Baxalta (BXLT) M&A deal),TCK +1.6% (Teck Resources: Sandstorm Gold (SAND) has agreed to acquire 56 royalties from co for $22 mln),MSFT +1.4% (will be acquiring MinecraftEdu)

Select China related names showing strength: JKS +9.5%, MOMO +5.5%, CSIQ +5.2%, JMEI +4.8%, SPWR +4.7%, QUNR +3.4%, JASO +3.4%, JD +3.3%, BABA +2.5%

Select metals/mining stocks trading higher: MT +9.7%, CLF +7.1%, AU +4.9%, FCX +4.8%, BBL +3.1%, BHP +3%, AA +1.7%, VALE +0.8%

Other news: CRDC +40% (Receives FDA clearance for expanded indications of Surgical Stapling Device),CANF +18.1% (announced that the USPTO has issued a Notice of Allowance for a patent titled, "A3 Adenosine Receptor Allosteric Modulators"),BSI +10.8% (Court grants temporary stay of legal proceedings against Mega Retail; also confirms it has received an number of offers to purchase the Company's holdings in Blue Square Real Estate),ZPIN +8.8% (received going private proposal valued at $17.50 per ADS and $8.75 per ordinary share),ATV +7% (cont strength),SNY +5.6% (strong EU mkts overnight),PUK +5.1% (still checking),TTM +5.1% (appoints new CEO),NRZ +5% (announces $200 mln share repurchase program),WMB +4.4% (Board is unanimously committed to completing the transaction with Energy Transfer Equity (ETE)),DDD +4.1% (still checking),INCY +2.9% (Incyte and Lilly (LLY) announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib),BBRY +2.5% (reports co was awarded a $20 million multiple-year delivery order),CARA +2.1% (may be related to BITI merger), RIO +2.4% (reports Q4 production results),YHOO +2.1% (in symp with BABA),NVS +2% (received two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US),GPRO +1.9% (strength in broader mkt this am),NFLX +1.9% (positive WSJD story),FB +1.8% (WhatsApp to pull its yearly subscription fee, test other monetization),BIIB +1.7% (reports EU approval for BENEPALI ),NGG +1.1% (Canadian funds are considering taking stake in NGG, according to Telegraph),SN +1.1% (reports average production of average production of 58,115 boe/day during the 4Q15; lowers 2016 Capital Budget guidance)

Analyst comments: EXEL +5.9% (upgraded to Outperform from Mkt Perform at Leerink Partners),SHOP +5.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley ),SHAK +4.8% (upgraded to Outperform from Market Perform at William Blair),P +4.8% (upgraded to Neutral at BTIG Research),KITE +4.4% (upgraded to Outperform from Mkt Perform at FBR Capital; tgt $75),SWIR +4.4% (upgraded to Outperform from Market Perform at Northland Capital),SWKS +3% (upgraded to Buy at Needham),AZN +1.9% (upgraded to Equal Weight, ResMed (RMD) downgraded to Underweight at Barclays)



 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/20/16 10:28 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

8:45 am Gapping down (SCANX) :

Gapping down
Briefing note: With US Futures down ~1.5% in pre-mkt, most stocks are trading lower. The following represents stocks lower on more specific items.

In reaction to disappointing earnings/guidance: IBM -6%, AMD -4.6%, EAT -4.6%, IBKR -4.4%, RDS.A -3.7%, PACB -2.7%, GS -1.6%

Select financial related names showing weakness: HSBC -3.8%, CS -3.8%, DB -3.3%, BAC -3.3%, BCS -3.2%, C -2.9%, ING -2.7%, LYB -2.7%, JPM -2.3%

Select oil/gas related names showing early weakness: WLL -9.7%, LEI -8.1%, DVN -5.8%, CHK -5.2%, PBR -4.7%, STO -4.2%, TOT -3.2%, APC -2.9%, SLB -2.9%

Other news: THS -7.8% (to offer up to $750 mln in common stock to fund part of its acquisition of ConAgra's (CAG) Private Brands business), SUNE -6.5% (still checking), BHP -6% (reported FY15 op metrics), DOC -5.7% (upsizes and prices 18.5 mln shares of common stock at $15.75), MU -4.3% (following AMD results), SSS -3.5% ( commences a public offering of 2.3 mln shares of common stock), BABA -3.3% (weakness in Chinese mkts overnight), BIDU -2.7% (weakness in Chinese mkts overnight)

Analyst comments: SDRL -10.8% (downgraded to Underperform at BofA/Merrill), FTNT -6.7% (downgraded to Neutral from Overweight at Piper Jaffray), VALE -6% (downgraded to Hold from Buy at HSBC Securities), RACE -2.2% (initiated with a Neutral at Citigroup; tgt $37), TIF -2% (downgraded to Neutral from Buy at Goldman), PRU -1.9% (downgraded to Neutral from Buy at BofA/Merrill)

8:41 am Gapping up (SCANX) : Gapping up
In reaction to strong earnings/guidance
: GNC +14.6%, CLMT +5%, AMTD +2%, CREE +1.7%, ASML +1.7%, LLTC +1.6%, NLS +1.5%, ADTN +1.5%, TEL +0.8%, APH +0.7%

Select gold mining stocks trading higher: HMY +9.3%, IAG +5.2%, HL +3.3%, ABX +3%, GG +2.8%, GFI +2.5%, NEM +2.4%, AEM +2%, GLD +1.2%

Other news: ZFGN +37% ( positive efficacy results from the bestPWS ZAF-311 Phase 3 trial),SYN +21.7% (The second Phase 2 clinical trial of SYN-010 for the treatment of irritable bowel syndrome with constipation met its primary endpoint),CBAY +17.3% (Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate),SFUN +5.5% (made significant progress on acquisition of controlling stake in Chongqing Wanli New Energy),PESI +5.1% (part of winning team led by CH2M Hill selected by US Navy for a $240 mln, 5-year Comprehensive Long-Term Environmental Action Navy (:CLEAN) contract),CLMT +5% (declared $0.685 dividend, unchanged from prior dividend; reaffirmed objective of providing all unitholders a stable-to-growing quarterly cash distribution),SCS +2.1% (Board approved a $150 mln increase to its share repurchase program)

Analyst comments: BSFT +2% (upgraded to Outperform from Market Perform at Wells Fargo)


after hours movers:

http://www.streetinsider.com/Special+Reports/

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) 41.8% LOWER; announced that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of 2016.


Endocyte, Inc. (NASDAQ: ECYT) 10% HIGHER; new Outperform rating at Credit Suisse


Xilinx Inc (NASDAQ: XLNX) 6.8% HIGHER; reported Q3 EPS of $0.49, in-line with the analyst estimate of $0.49. Revenue for the quarter came in at $566.2 million versus the consensus estimate of $554.5 million.


FireEye, Inc. (NASDAQ: FEYE) 5% HIGHER; announced the acquisition of privately held iSIGHT Partners, one of the world's leading providers of cyber threat intelligence for global enterprises. The transaction closed on January 14, 2016. Also, total fourth quarter revenue is expected to be in the range of $184 million to $185 million and total fourth quarter billings are expected to be within the range of $256 million to $257 million. Further, the company also expects positive operating cash flow in the range of $7 to $9 million for the fourth quarter, resulting in positive operating cash flow of between $35 million and $37 million for 2015. *** The Street sees Q4 revenue of $187 million and loss of $0.37 per share.


Sallie Mae (NASDAQ: SLM) 3% LOWER; reported Q4 EPS of $0.20, $0.02 better than the analyst estimate of $0.18. Sallie Mae sees FY16 core EPS of $0.49 - $0.51, versus expectations of $0.65.


Sarepta Therapeutics (NASDAQ: SRPT) 2.7% LOWER; FDA Panel Postponed Due to Weather


F5 Networks (NASDAQ: FFIV) 1.8% HIGHER; reported Q1 EPS of $1.73, $0.13 better than the analyst estimate of $1.60. Revenue for the quarter came in at $489.5 million versus the consensus estimate of $485.51 million. GUIDANCE: F5 Networks sees Q2 2016 EPS of $1.61-$1.64, versus the consensus of $1.68. F5 Networks sees Q2 2016 revenue of $480-490 million, versus the consensus of $499.5 million.


Zafgen, Inc. (NASDAQ: ZFGN) 1.6% HIGHER; adds to gains after jumping 79% intra-day


Kinder Morgan (NYSE: KMI) 1.2% HIGHER; reported adjusted Q4 DCF of $0.55, in-line with the analyst estimate of $0.55. Revenue for the quarter came in at $3.64 billion versus the consensus estimate of $3.9 billion. Kinder Morgan (NYSE: KMI) declared a quarterly dividend of $0.125 per share, or $0.5 annualized. This is a 75.5% decrease from the prior dividend of $0.51.



Last edited by sunnyday on 1/20/16 21:39, edited 2 times in total

 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/20/16 10:32 
Offline 模拟帐户

Joined: 8/5/07 20:13
Posts: 40598

sunnyday wrote:
http://finance.yahoo.com/news/inplay-br ... 1735.html# There are no updates this morning.
小编亏费了,罢工了?


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/20/16 10:59 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

发哥 wrote:

sunnyday wrote:
http://finance.yahoo.com/news/inplay-br ... 1735.html# There are no updates this morning.
小编亏费了,罢工了?
Smile fage, how have you been since 2016?


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/21/16 10:11 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

8:31 am Gapping down (SCANX) : Gapping down
In reaction to disappointing earnings/guidance
: AVP -2.1%, PCBK -1.9%, BC -1.8%, LEJU -1.8%, UNP -1.5%, BGG -0.8%, BKMU -0.4%


Other news: OGXI -36.5% (announces that data from the Phase 2 Spruce trial did not reach statistical significance required to demonstrate a progression-free survival benefit), ALKS -29% (announces topline results of FORWARD-3 and FORWARD-4, two phase 3 studies in major depressive disorder; neither study met primary endpoint), FPRX -6.7% (comments on the U.S. Attorney's indictment of two former GlaxoSmithKline (GSK) employees with theft of trade secrets from GSK which theft included information related to FP-1039, FivePrime's FGF ligand trap product candidate), DB -6.1% (reaction to earnings yday), RESI -5% (confirms Shareholders Group has nominated 3 candidates to stand for election to the Company's Board of Directors; No stockholder action required at this time), GRUB -4.6% (following report that Uber will expand its delivery service to 10 cities), CFR -4.1% (reported Q4 provision for loan losses is expected to be $34.0 mln), MBT -3.8% (still checking, light volume), SQM -2.9% (updates on 2016 expectations for some of its key businesses), ALU -2.3% (may be in symp with ERIC dg), SRPT -2% (FDA delays Friday's AdComm meeting for eteplirsen due to inclement weather forecasted for the Washington, DC area), ING -1.1% (in symp with DB), HSBC -1.1% (in symp with DB)

Analyst comments: ERIC -2% (downgraded to Sell at Goldman), TMH -1.1% (target lowered to $65 from $80 at Jefferies)

8:27 am Gapping up (SCANX) :

Gapping up
In reaction to strong earnings/guidance
: PSO +14.1%, FEYE +11%, XLNX +9.9%, LOGI +7.9%, KEY +6.9%, CY +4.7%, PLXS +3.3%, TCBI +2.9%, LUV +1.8%, FITB +1.8%, MTG +1.4%, VZ +1.1%, CATY +1%, ALK +0.9%, CVBF +0.7%, TRV +0.7%, FFIV +0.5%

M&A news: TWTR +4.7% (WSJ Heard on the Street column profiles view that TWTR might be a possible takeover target)

Other news: ZFGN +22.8% (cont strength, but also upgraded to Outperform from Mkt Perform at FBR Capital, and RBC Cap'l),GBSN +19.1% (prices all remaining Series C warrants to shares of its common stock),AGEN +16.1% (announces 2 new investigational drug applications by FDA),RWT +6.7% (offered preliminary 2016 outlook, announces restructuring of conforming loan operations),BLDP +4.2% (receives follow-on order from Nisshinbo),MU +2.1% (modest rebound pre-mkt),DDD +1.9% (modest rebound pre-mkt),FAF +1.7% (raises quarterly dividend by 4% or $0.01 to $0.26 per share)

Analyst comments:FIT +3.6% (upgraded to Outperform from Mkt Perform at Raymond James),ASML +3.1% (upgraded to Buy from Neutral at UBS),SPWR +3% (upgraded to Buy from Neutral at Janney),ECYT +2.4% (initiated with an Outperform at Credit Suisse),WRB +1.6% (upgraded to Equal-Weight from Underweight at Morgan Stanley),MDVN +1.5% (initiated with an Outperform at Credit Suisse),AGIO +1.3% (initiated with an Outperform at Credit Suisse)



 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 1/22/16 10:04 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

http://finance.yahoo.com/news/inplay-br ... 1735.html#

8:20 am Gapping down (SCANX) : Gapping down
In reaction to disappointing earnings/guidance
: CSII -19.7%, DGII -9.1%, AXP -5.7%, ETFC -2.5%, SBUX -1.8%, GE -1%


Other news: ECR -3.8% (reports proved reserves declined 2% YoY; expects to see Q4 impairment due to), LGCY -21.1% (announced 2016 distribution suspension; capital budget of $37 mln), AGRX -14.7% (intends to offer and sell $30 million of shares of its common stock), REXX -13.3% (suspends payment of its quarterly dividend on shares of its 6.0% Series A convertible perpetual preferred stock), PSO -2.9% (modest pull back following yday's gains), ABX -2.5% (announced preliminary 2015 full-year production of 6.12 mln ounces of gold, in line with the co's updated guidance of 6.0-6.15 mln ounces), SBNY -1.5% (prices 2.2 mln shares of common stock at $136 per share)

Analyst comments: SKX -1% (downgraded to Neutral from Positive at Susquehanna)

8:15 am Gapping up (SCANX) : Gapping up
In reaction to strong earnings/guidance
: EGHT +9.8%, RMD +5.6%, MITL +4.8%, SLB +3.7%, LM +3.1%, MXIM +3%, VASC +1.6%, ISRG +1.4%, SYF +0.9%

M&A news: CAB +3% (looking to sell its credit card unit ahead of a full sale, according to the NYPost ),YHOO +2.3% (has rebuffed several buyers for its core internet assets, will decide on potential strategic moves following its Q4 report, according to Reuters)

Select metals/mining stocks trading higher: VALE +5%, BBL +4.9%, FCX +4.6%, BHP +3%, AA +2.3%

Select oil/gas related names showing strength with crude futures ~+5%: WLL +8.8%, CHK +7.9%, PBR +7.7%, MRO +6.8%, ETE +6.7%, RDS.A +5.1%, HAL +5%, STO +4.8%, LINE +4.7%, KMI +4.6%, TOT +4.1%, BAS +4.1%, COP +3.9%, BP +3.7%, SDRL +3.5%, RIG +3%, XOM +2.7%, VLO +2.5%

Other news: GBSN +21.3% (converted all outstanding Series C Warrants into shares of its common stock and therefore now has 75.5 million shares of common stock issued and outstanding, and has no remaining unconverted Series C Warrants),GALE +14.4% (presented data from an observational study in gastric cancer patients at the American Society of Clinical Oncology 2016 Gastrointestinal Cancers Symposium),BLDP +13% (receives $12 mln fuel cell contract in China; expected to deliver 2016-2017),SUNE +6.6% (cont pre-mkt vol),XNPT +5.6% (following Reuters report suggesting possible sale),VSTM +5.5% (to present preclinical data that demonstrated extended survival with the combination of its FAK inhibitor with anti-PD-1 therapy at Immunotherapy World on January 25),ZFGN +4.8% (cont momentum),RP +2.7% (Brian Shelton will be named Interim Chief Financial Officer and Treasurer effective February 29),FIT +2.3% (cont pre-mkt vol),AMZN +2.1% (confirmed EU investment plans; to create several thousand more new jobs in 2016),CEMP +1.6% (enters into an API manufacturing and supply agreement with FUJIFILM Finechemicals)

Analyst comments: ERIC +5.4% (upgraded to Buy at Swedbank),SCTY +4.2% (initiated with an Overweight at Barclays),BCS +3.7% (upgraded to Hold at Berenberg),ABB +3.2% (upgraded to Neutral from Sell at UBS ),JD +3% (upgraded to Buy from Neutral at Nomura),ASML +2.8% (upgraded to Hold at Deutsche Bank),CTRP +2.5% (initiated with a Buy at Nomura),QCOM +2% (upgraded to Outperform from Market Perform at Northland Capital ),DPS +1.6% (upgraded to Outperform from Underperform at Credit Agricole),BMY +1.4% (upgraded to Buy from Hold at Berenberg)


01/16--01/20/2017
This week's top 20 % gainers

Materials: CENX (13.74 +19.27%), CX (8.84 +10.92%)

Industrials: CSX (43.97 +13.32%), GOGL (5.49 +9.58%)

Consumer Discretionary: MMYT (30.1 +9.45%), STON (11.45 +8.74%)

Information Technology: SWKS (88.49 +12.97%), OCLR (9.37 +10.37%), WNS (29.54 +8.96%)

Financials: GCAP (7.34 +8.74%)

Energy: CWEI (146.85 +41.23%), SN (13.21 +17.53%), LPG (10.82 +15.85%), OSG (5.45 +13.07%), TK (10.16 +12.89%), TGP (17.05 +11.8%), DHT (4.4 +10.28%)

Consumer Staples: UVV (75 +12.44%)

Utilities: NRG (16.11 +10.34%), ABY (21.65 +9.29%)

This week's top 20 % losers


Healthcare: BIOS (1.26 -22.7%), SGMO (3.68 -16.48%), TGTX (4.2 -15.15%), BIOB (0 -14.29%), SRPT (32.65 -13.69%), KERX (5.44 -13.18%), BMY (49.23 -12.43%), ARWR (1.81 -12.14%), SGYP (5.93 -11.89%), AIMT (18.82 -11.52%)

Consumer Discretionary: PSO (7.23 -27.19%), EVC (5.1 -20.93%), RCII (8.39 -19.3%), GNC (9.47 -17.08%), TUES (4.45 -16.82%)

Information Technology: GIMO (34.2 -24.59%), PRGS (28.13 -12.78%)

Energy: CCJ (11.74 -11.66%), TESO (8.35 -11.64%)

Consumer Staples: RAD (7.22 -16.63%)


Last edited by sunnyday on 1/23/17 00:35, edited 3 times in total

 
 Profile  
Reply to topic 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 544 Posts ]  Go to page 1, 2, 3, 4, 5 ... 37  Next

Home 


Who is online

Users browsing this forum: No registered users and 2 guests


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:

Batch Generator
Hutong9 SizzlingStock GaoFamily  Hearty  TT  股通 财籽 GrusInvest E.T. Yahoo Google msn 大千 未名 外汇牛人邦 CNFinance 华人 investern optionpain YangCai 司空金融网


This site is mainly for stock market discussion, it does not provide any investment advice. It is not suggested to rely on posts here for investment decision.
本网站主要作为股市讨论用途,并不提供任何投资建议。请不要将本站内容作为投资依据,否则风险自负。

钱多多股票论坛 - Trader1688.com© Powered by phpBB © 2002, 2006 phpBB Group